On the upside
J. P. Morgan upgraded RealNetworks (Nasdaq: RNWK) saying that the company should receive a favorable ruling in its arbitration with VeriSign (NYSE: VRSN).
Avanir Pharmaceuticals (Nasdaq: AVNR) reported upbeat results from a Phase III clinical trial of its amyotrophic lateral sclerosis treatment Zenvia.
Citigroup analyst Michael Rollins upgraded Sprint (NYSE: S) and lifted his price target on the company saying that sales should improve next year and that the company may seek a merger deal.